SOLENO THERAP
PharmaSOLENO THERAP is a pharmaceutical company with 1 FDA-approved products.
SOLENO THERAP's Key Drugs
SOLENO THERAP's core commercial portfolio centers on VYKAT XR — its most strategically important drugs approved in the last 15 years.
SOLENO THERAP's Recent FDA Approvals
SOLENO THERAP secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SOLENO THERAP's Therapeutic Areas
Disease areas where SOLENO THERAP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SOLENO THERAP Pipeline Snapshot
Active clinical trials for SOLENO THERAP across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VYKAT XR leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-03-26
- Latest
- 2025-03-26
- Applications
- 1